For both sides

Rescheduling impact calculator

Federal and state law current as of September 2026 — verify with counsel.

The rescheduling impact calculator estimates the extra federal tax section 280E costs a cannabis business today: disallowed SG&A times adult-use share times the tax rate. It subtracts that tax from pre-280E EBITDA and compares the result with EBITDA if adult-use marijuana also moved to Schedule III. With the defaults, the extra tax is $58,800, giving $441,200 today against $500,000. It is a scenario, not a forecast.

Key takeaways

  • Formula: extra federal tax = SG&A disallowed under 280E x adult-use share x federal tax rate; cash proxy today = EBITDA - extra tax; hypothetical = EBITDA.
  • Default result: $400,000 x 0.7 x 0.21 = $58,800 of extra tax a year, so $441,200 today versus $500,000 if adult-use were also Schedule III.
  • The tax rate is an input: at a 37% owner rate the same business loses $103,600 a year to 280E, not $58,800.
  • The DEA hearing on broader rescheduling ran from 29 June to 15 July 2026; no judge's recommendation or final rule had issued as of mid-September 2026.
  • Headset estimated that a typical dispensary would save about $268,000 a year under Schedule III treatment, as reported by Cannabis Business Times.

What the rescheduling calculator computes

The tool produces three numbers:

  • Extra federal tax from 280E today. The tax caused by operating expenses that get no federal deduction because they relate to adult-use sales.
  • Cash proxy today. Your pre-280E EBITDA less that extra tax.
  • Hypothetical EBITDA if adult-use were also Schedule III. The same business if adult-use marijuana were moved out of Schedule I and II, so that section 280E no longer applied to any of it.

The legal background: the April 2026 order moved FDA-approved products and marijuana subject to a state medical license to Schedule III. Adult-use marijuana stayed in Schedule I. A separate proceeding on broader rescheduling went to a hearing that ran from 29 June to 15 July 2026. Post-hearing briefs were due 17 August, and as of mid-September 2026 the judge’s recommendation was still pending with no final rule. Current status is tracked on rescheduling status and what it changes.

The formula

  • Extra federal tax from 280E = SG&A disallowed under 280E x adult-use share x federal tax rate
  • Cash proxy today = pre-280E EBITDA - extra federal tax
  • Hypothetical = pre-280E EBITDA

The proxy is not full after-tax cash flow. It removes only the tax that 280E adds, so the difference between the two figures is exactly what full rescheduling would save each year on these inputs.

Inputs

InputWhat to enter
Pre-280E EBITDANormalized trailing twelve month EBITDA before federal income tax
SG&A disallowed under 280EOperating expenses outside cost of goods sold that would be non-deductible if the whole business were adult-use: store payroll, rent, marketing, administration. Take it from the tax return workpapers, not the income statement
Adult-use shareA decimal from 0 to 1. The share of activity that is adult-use and so still subject to 280E. Enter 1 for an adult-use-only business and 0 for medical-only
Federal tax rateA decimal. The default 0.21 is the federal corporate rate. Owners of pass-through entities should enter their own marginal rate, for example 0.37

Worked example

Illustrative, using the tool’s defaults: EBITDA $500,000, disallowed SG&A $400,000, adult-use share 0.7, federal tax rate 0.21.

StepArithmeticResult
Adult-use expenses with no deduction$400,000 x 0.7$280,000
Extra federal tax from 280E$280,000 x 0.21$58,800 a year
Cash proxy today$500,000 - $58,800$441,200
Hypothetical if adult-use were Schedule IIIunchanged$500,000

Change the rate input to 0.37 for an owner in the top individual bracket and the extra tax becomes $280,000 x 0.37 = $103,600, leaving a proxy of $396,400. So for this business, full rescheduling would be worth roughly $59,000 to $104,000 a year in federal tax, depending on entity type and the owners’ rates. For scale, Headset estimated that a typical dispensary would save about $268,000 a year under Schedule III treatment, as reported by Cannabis Business Times. Your figure depends on how much expense sits outside cost of goods sold, which is why retailers gain more than growers; see 280E by license type.

For a line-by-line tax estimate under current law, use the 280E effective tax rate calculator.

From tax savings to value

A buyer would capitalise the after-tax saving, then discount it for the chance it never arrives. Illustrative only: $58,800 a year at a 4x multiple is $235,200; at a one-in-three assumed probability that is about $78,000 of extra value today. The probability is a judgment, not a published figure. The market has not paid up in advance so far. Viridian Capital’s median multiple for larger U.S. MSOs was 5.1x 2026 EBITDA in November 2025, lower than in mid-2024, even as rescheduling moved forward.

Where buyer and seller disagree on the odds, a contingent payment tied to a final rule can bridge the gap; see earn-outs in cannabis deals. The wider valuation argument is on how rescheduling would affect valuation, the timing decision is on selling before or after rescheduling, and tax scenarios including refund claims and state conformity are on rescheduling tax scenarios.

Limitations

  • Not a prediction. The tool’s own output says so. No outcome or date is implied.
  • Proxy, not cash flow. The today figure deducts only the 280E-driven tax, not ordinary income tax, interest, or capital spending.
  • One flat rate. Real tax is computed on the whole return; a single rate times disallowed expenses is an approximation.
  • Apportionment is assumed. Dual operators must split expenses between medical and adult-use. Treasury previewed the approach on 23 April 2026, but detailed IRS guidance had not issued by mid-September 2026.
  • Federal only. State income tax treatment varies and many states already allow the deductions.
  • Static. It ignores competitive effects. If every operator’s tax falls, some of the saving may pass to customers through lower prices.
  • Nothing else changes. Schedule III would not by itself permit interstate sales, SBA loans, or federal bankruptcy.

This page and the tool are educational and are not tax, legal, or valuation advice. To talk through what the scenarios mean for a sale or purchase you are considering, you can book a confidential intro call.

Illustrative result will appear here.

Illustrative only. Defaults are commentary ranges, not a valuation or tax opinion. Federal and state law current as of September 2026.

Frequently asked questions

Does the calculator predict that adult-use cannabis will be rescheduled?

No. It shows what your numbers would look like under one hypothetical outcome. As of mid-September 2026 the hearing record was closed and post-hearing briefs were in, but the administrative law judge had issued no recommendation, the DEA Administrator faces no deadline, and any final rule could be challenged in court. Adult-use marijuana remained in Schedule I.

Why is the extra tax in the calculator smaller than my total federal tax bill?

Because it isolates the part caused by section 280E. The tool multiplies the adult-use share of your non-deductible expenses by the tax rate. With the defaults, $280,000 of expenses that get no deduction, taxed at 21%, is $58,800. You would still owe ordinary income tax on real profit under any scheduling outcome, and the tool does not show that.

I am medical only. Is there anything for me to calculate?

Set the adult-use share to zero and both figures are equal, which reflects the law since April 2026: qualifying state-licensed medical activity is in Schedule III and outside section 280E going forward. Your open questions are about transition rules and earlier tax years, which the tool does not address. Treasury has previewed guidance but the IRS had not published it by mid-September 2026.

Should I wait for rescheduling before I sell my business?

The calculator shows the size of the prize, not the odds or the timing. Waiting has costs: another year of 280E tax, price compression in many states, and the risk that buyers have already priced the change in or that multiples fall. Public cannabis multiples declined from mid-2024 to late 2025 even as rescheduling advanced. The decision is covered in detail elsewhere on this site.

Would full rescheduling raise the value of my business by the same amount?

Not one for one. A buyer would capitalise the tax saving and would discount it for uncertainty. Rescheduling would also help every competitor, which may push prices down, and it would not by itself open interstate commerce, SBA lending, or bankruptcy protection. Some deals handle the uncertainty with a contingent payment.

Sources

  1. Federal Register — Schedules of Controlled Substances, 2026-08176 (28 April 2026) — https://www.federalregister.gov/d/2026-08176
  2. Federal Register — 2026-08177, Schedules of Controlled Substances: Rescheduling of Marijuana, hearing notice (28 April 2026) — https://www.federalregister.gov/documents/2026/04/28/2026-08177/schedules-of-controlled-substances-rescheduling-of-marijuana
  3. Marijuana Moment — DEA Releases Full Marijuana Rescheduling Hearing Transcript As Judge Prepares To Issue His Recommendation (Aug 2026) — https://www.marijuanamoment.net/dea-releases-full-marijuana-rescheduling-hearing-transcript-as-judge-prepares-to-issue-his-recommendation/
  4. Legal Information Institute — 26 U.S.C. 280E — https://www.law.cornell.edu/uscode/text/26/280E
  5. U.S. Department of the Treasury — Process for Tax Guidance Following DOJ Final Order, press release sb0471 (23 April 2026) — https://home.treasury.gov/news/press-releases/sb0471
  6. Cannabis Business Times — Typical Dispensary to Save $268K Annually Under Schedule III Reclassification (Headset report) — https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15774718/typical-dispensary-to-save-268k-annually-under-schedule-iii-reclassification
  7. Highly Capitalized — Viridian Capital Advisors valuation metrics for U.S. MSOs (18 Nov 2025) — https://highlycapitalized.com/viridian-capital-advisors-reports-valuation-metrics-for-u-s-msos-with-market-caps-100m/